KalVista Presents Five Real-World and Clinical Studies of Sebetralstat in Hereditary Angioedema at ACAAI 2026

Key Takeaways
- KalVista Pharmaceuticals, a company of the Chiesi Group, presented five ePosters on sebetralstat (Ekterly), an oral on-demand treatment for hereditary angioedema attacks, at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix.
- The presentations covered patient satisfaction, reasons for switching to sebetralstat, long-term quality of life, healthcare use among adolescents, and the burden of injectable treatments on children and caregivers.
- The company’s announcement describes the topics and study designs but doesn’t report the results. Several of the studies are sponsored by or drawn from the company’s own programs.
KalVista Pharmaceuticals, based in Framingham, Massachusetts, announced five presentations of clinical and real-world research on sebetralstat at ACAAI 2026, which ran November 12 to 16. KalVista is now part of the Chiesi Group, which acquired it and placed it within Chiesi Global Rare Diseases. Sebetralstat (Ekterly) is a plasma kallikrein inhibitor approved to treat acute HAE attacks in people 12 and older in the United States, the European Union, the United Kingdom, Switzerland, Australia, Singapore, and Japan. HAE is a rare genetic disease caused by deficiency or dysfunction of the C1 esterase inhibitor protein, which leads to painful and sometimes life-threatening swelling attacks.
All five were ePosters with Meet the Author sessions. Two came from EARLY, an ongoing Phase 4, prospective, real-world, observational study of sebetralstat in adolescents and adults. Joshua S. Jacobs, M.D., of Allergy and Asthma Clinical Research in Walnut Creek, California, presented patient satisfaction data from attack diaries collected between January and June 2026. They came from US participants aged 12 and older who had been prescribed or were taking sebetralstat for three months before enrollment. William R. Lumry, M.D., of the University of Texas Southwestern Medical School, presented baseline data on why 56 US participants switched to sebetralstat for on-demand treatment.
A third poster, by Adil Adatia, M.D., of the University of Alberta, analyzed treatment patterns and healthcare resource use among adolescents aged 12 to 17 with HAE, using the IQVIA PharMetrics Plus claims database from 2021 to 2024. Jonathan A. Bernstein, M.D., of the University of Cincinnati, presented quality-of-life findings from KONFIDENT-S, a two-year open-label extension study in which participants completed the angioedema quality of life questionnaire at baseline and about every four weeks afterward. The fifth poster, by Timothy J. Craig, D.O., of Penn State, drew on a literature review and interviews with HAE experts to examine the burden of injectable on-demand treatment on children aged 11 and younger and their caregivers. Sebetralstat’s label doesn’t cover that age group.
Rachele Berria, M.D., Ph.D., of the Chiesi Group said the studies look beyond efficacy to the emotional and practical factors that shape how people manage attacks. Lumry said real-world and patient-reported evidence helps clinicians evaluate the full impact of care. Giacomo Chiesi, executive vice president of Chiesi Global Rare Diseases, said the acquisition marks a milestone for the company’s rare disease work.